New hope for head & neck cancer patients who Can't take standard chemo
NCT ID NCT07445048
Summary
This study is for people with high-risk head and neck cancer who have had surgery but cannot take the standard chemotherapy drug cisplatin. It will test if adding two newer drugs (nimotuzumab and bemcentinib) to standard radiation therapy after surgery is better at keeping the cancer from coming back. The main goal is to see if this new combination helps patients live longer without their cancer returning, compared to standard care alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.